logo

Aimmune Therapeutics Inc. (AIMT)



Trade AIMT now with
  Date
  Headline
3/12/2018 8:09:56 AM Aimmune Therapeutics Q4 Net Loss $41.2 Mln Or $0.81 Per Share
3/6/2018 7:23:26 AM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $72 Price Target
2/27/2018 8:26:49 AM RBC Capital Markets Is Raising Aimmune Therapeutics Inc. (AIMT) FY20 Rev. Estimate To 449.54 M From 397.82 M
2/27/2018 8:26:35 AM RBC Capital Markets Is Increasing Aimmune Therapeutics Inc. (AIMT) FY19 Rev. Estimate To 142.01 M From 126.00 M
2/27/2018 8:25:45 AM RBC Capital Markets Is Raising Aimmune Therapeutics Inc. (AIMT) FY20 Estimate To 2.69 From 2.29
2/27/2018 8:25:34 AM RBC Capital Markets Is Raising Aimmune Therapeutics Inc. (AIMT) FY19 Estimate To -1.35 From -1.86
2/27/2018 8:25:15 AM RBC Capital Markets Is Increasing Aimmune Therapeutics Inc. (AIMT) FY18 Estimate To -3.50 From -3.67
2/27/2018 8:24:58 AM RBC Capital Markets Is Raising Aimmune Therapeutics Inc. (AIMT) Q4 18 Estimate To -0.96 From -1.01
2/27/2018 8:24:42 AM RBC Capital Markets Is Raising Aimmune Therapeutics Inc. (AIMT) Q3 18 Estimate To -0.89 From -0.94
2/27/2018 8:24:29 AM RBC Capital Markets Is Raising Aimmune Therapeutics Inc. (AIMT) Q2 18 Estimate To -0.84 From -0.88
2/27/2018 8:24:16 AM RBC Capital Markets Is Increasing Aimmune Therapeutics Inc. (AIMT) Q1 18 Estimate To -0.82 From -0.86
2/21/2018 7:35:04 PM Aimmune Therapeutics Prices Public Offering Of 5.50 Mln Shares At $32.00/shr
2/20/2018 10:16:37 AM Investors Going Nuts For Aimmune
2/20/2018 7:15:02 AM Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial Of AR101 Meets Primary Endpoint In Patients With Peanut Allergy
2/7/2018 6:16:15 AM RBC Capital Markets Starts Aimmune Therapeutics Inc. (AIMT) At Outperform With $55 Price Target
12/1/2017 12:23:14 PM Wedbush Reiterates Aimmune Therapeutics Inc. (AIMT) At Outperform With $70 Price Target